OakChart

Sana Biotechnology Inc

SANAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 1:34 PM ET

2.32-0.11 (-4.53%)
2026-11-11 19:34 CET
Market cap
728.11 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-149.27 USD m
Free cash flow, TTM
-145.13 USD m
EPS diluted, TTM
-0.53
P/E
-
Compare

Price

SANA against its 20, 50 and 200-day averages
2050200beatmiss
2.503.003.504.0011.4M22.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SANAclose 2.3220-day 2.4350-day 2.80200-day 3.302.3252w low

57.7% under the 52-week high of 5.49 on 4 Dec 2025. 52-week low 2.22 on 19 Oct 2026. Last 15 sessions, 23.3% high to low

Profile

SANA
52-week range, 3% of the way up
2.225.49

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

IndexRUT
Employees142
IPOFeb 04, 2021
Beta2.30
ATR, 14d0.18
Rel volume0.63
Short float21.72%
Insider own37.61%
Inst own50.94%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap695.15M
Enterprise Value623.50M
Income-149.27M
Sales0.00M
Book/sh0.60
Cash/sh0.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees142
IPOFeb 04, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.85
P/C5.54
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.77
Current Ratio1.77
Debt/Eq0.30
LT Debt/Eq0.22
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.53
EPS next Y-0.52
EPS next Q-0.16
EPS this Y44.27%
EPS next Y2.60%
EPS next 5Y18.41%
EPS past 3/5Y12.33% 8.72%
Sales past 3/5Y- -
EPS Y/Y TTM45.15%
Sales Y/Y TTM-
EPS Q/Q140.85%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.147.36% -

Ownership

Insider Own37.61%
Insider Trans0.00%
Inst Own50.94%
Inst Trans0.51%
ROA-36.79%
ROE-79.47%
ROIC-67.58%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-4.39%
SMA50-16.99%
SMA200-29.68%
Trades-

Technical

Shs Outstand299.52M
Shs Float186.96M
Short Float21.72%
Short Ratio12.63
Short Interest40.60M
52W High5.49 -57.74%
52W Low2.22 4.50%
Volatility8.93% 7.49%
ATR (14)0.18
RSI (14)40.66
Beta2.30
Rel Volume0.63
Avg Volume3.21M
Volume1,299,199

Performance

Perf Week-9.38%
Perf Month-3.73%
Perf Quarter-36.78%
Perf Half Y-27.50%
Perf YTD-43.00%
Perf Year-45.28%
Perf 3Y-31.16%
Perf 5Y-89.34%
Perf 10Y-
Recom1.20
Target Price9.38
Prev Close2.43
Price2.32
Change %-4.53%

Analyst ratings

latest 10 of 17
DateActionAnalystRating changeTargetImplied
May 11, 2026InitiatedRRodman & RenshawBuy$16+589.7%
Sep 24, 2025InitiatedWWedbushOutperform$5+115.5%
Jul 03, 2025ResumedMMorgan StanleyOverweight$12+417.2%
Mar 18, 2025UpgradeCCitizens JMPMkt Perform → Mkt Outperform$5+115.5%
Mar 14, 2025InitiatedJJefferiesBuy$7+201.7%
Jan 08, 2025UpgradeTTD CowenHold → Buy
Nov 05, 2024DowngradeJJMP SecuritiesMkt Outperform → Mkt Perform
Jun 26, 2024InitiatedRRodman & RenshawBuy$16+589.7%
Jan 16, 2024UpgradeHH.C. WainwrightNeutral → Buy$12+417.2%
Sep 25, 2023InitiatedJJMP SecuritiesMkt Outperform$9+287.9%

Peers

Mkt cap
TickerCompanyMkt cap
CRSPCRISPR Therapeutics AG4.43B
ALLOAllogene Therapeutics Inc312.06M
IPSCCentury Therapeutics Inc309.99M
FATEFate Therapeutics Inc199.98M
KYTXKyverna Therapeutics Inc320.96M
NCELNewcelX Ltd14.97M
CABACabaletta Bio Inc316.03M
BEAMBeam Therapeutics Inc2.67B
VORVor Biopharma Inc1.24B
LCTXLineage Cell Therapeutics Inc279.46M

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
PATEL DHAVALKUMAR DHIRAJLALEVP, Chief Scientific OfficerAug 26 '26Option Exercise0.00125,0000224,510Aug 27 04:21 PM
Harr StevePresident & CEOMar 07 '26Option Exercise0.0050,00007,968,596Mar 10 04:16 PM
Harr StevePresident & CEOMar 06 '26Option Exercise0.0041,66607,918,596Mar 10 04:16 PM
Wyrick Susan D.See RemarksMar 07 '26Option Exercise0.003,2500200,583Mar 10 04:15 PM
Wyrick Susan D.See RemarksMar 06 '26Option Exercise0.0010,4160197,333Mar 10 04:15 PM
Wyrick Susan D.See RemarksMar 02 '26Option Exercise0.001,5250187,408Mar 04 04:17 PM
Wyrick Susan D.See RemarksJan 02 '26Option Exercise0.007,5000188,290Jan 06 04:18 PM
Wyrick Susan D.See RemarksDec 13 '25Option Exercise0.003,4000181,663Dec 16 04:16 PM
Wyrick Susan D.See RemarksDec 03 '25Option Exercise0.0010,0000180,828Dec 05 05:04 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
SMLFiShares U.S. Small-Cap Equity Factor ETFAUM: 4.26B

News

latest 14 of 200
  • Sana: Q3 Earnings Snapshot (Associated Press) -8.59%
  • Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
  • Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
  • Sana Biotechnology to Present at September 2026 Investor Conferences (GlobeNewswire)
  • Sana: Q2 Earnings Snapshot (Associated Press)
  • Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
  • Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
  • Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes (GlobeNewswire) -5.45%
  • The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy (PR Newswire)
  • Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 (GlobeNewswire)
  • I worry deeply about bioterrorism: Is Europe sufficiently prepared for another pandemic? (Euronews) +6.34%
  • Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
  • Sana Biotechnology to Present at June 2026 Investor Conferences (GlobeNewswire)
  • Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-050.070-0.1480.0700.000.009
2026Q22026-08-10-0.220-0.147-0.2150.000.009
2026Q12026-05-11-0.170-0.162-0.1710.000.009
2025Q42026-03-03-0.210-0.142-0.2130.000.009
2025Q32025-11-06-0.160-0.189-0.1620.000.008
2025Q22025-08-11-0.390-0.201-0.3930.000.007
2025Q12025-05-08-0.210-0.219-0.2080.000.006
2024Q42025-03-17-0.210-0.246-0.2080.000.008
2024Q32024-11-08-0.250-0.257-0.2550.000.007
2024Q22024-08-08-0.210-0.292-0.2150.000.005
2024Q12024-05-08-0.490-0.302-0.4950.000.006
2023Q42024-02-29-0.450-0.384-0.4470.000.007
2023Q32023-11-080.000-0.4460.0050.000.007
2023Q22023-08-03-0.590-0.427-0.5920.000.003
2023Q12023-05-08-0.430-0.438-0.4290.000.004
2022Q42023-03-16-0.400-0.480-0.4220.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-2.325-5.260-1.5220.000.00
2021FY-2.140-1.768-2.1390.000.00
2022FY-1.810-1.795-1.4310.000.00
2023FY-1.460-1.539-1.4560.000.00
2024FY-1.160-1.186-1.1550.000.00
2025FY-0.960-0.863-0.9600.000.00
2026FY--0.535--0.00
2027FY--0.521--0.00
2028FY--0.521--0.00
2029FY--0.553--4.98
2030FY--0.490--26.25

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-068000.000.000.00
2026Q4S2026-08-118000.000.000.00
2026Q4S2026-06-258000.000.000.00
2026Q4S2026-06-127000.000.000.00
2026Q4S2026-05-128000.000.000.00
2026Q4S2026-03-058000.000.000.00
2026Q4S2026-03-047000.000.000.00
2026Q4S2026-02-185000.000.000.00
2026Q4S2025-11-114000.000.000.00
2026Q4S2025-11-104000.000.000.00
2026Q4S2025-11-094000.000.000.00
2026Q4S2025-11-084000.000.000.00
2026Q4S2025-11-074000.000.000.00
2026Q4S2025-11-062000.000.000.00

Estimate history

EPS, annual-0.071-0.698-1.522-2.139-1.431-1.456-1.155-0.964-0.5329
Period20182019202020212022202320242025TTM
EPS, quarterly-0.255-0.208-0.208-0.393-0.162-0.213-0.171-0.2150.066
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual187.34187.34187.506184.929191.022197.857223.923266.732299.521
Period20182019202020212022202320242025MRQ
Shares, quarterly223.108223.923225.463230.51262.264266.732269.817299.306299.521
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A10.6412.7515.4930.8627.7317.9110.173.920.00
Gross Profit-10.64-12.75-15.49-30.86-27.73-17.91-10.17-3.92-0.00
Selling, General and Administrative Excl. Other165.87178.21255.98294.94241.32228.68150.9595.508.22
Research and Development123.50133.91191.94221.64169.76178.27122.6874.324.01
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-176.51-190.96-271.47-325.81-269.06-246.60-161.12-99.42-8.22
Interest Expense-0.00-0.000.000.000.000.000.00
Unusual Expense-19.7859.361.25-32.663.51110.31136.9346.235.03
Net Income Before Taxes-149.27-244.17-266.76-283.25-269.48-355.93-297.20-142.82-13.25
Income Taxes0.000.000.000.000.000.00-11.90-12.050.00
Consolidated Net Income-149.27-244.17-266.76-283.25-269.48-355.93-285.31-130.78-13.25
Net Income From Continuing Operations-149.27-244.17-266.76-283.25-269.48-355.93-285.31-130.78-13.25
Net Income-149.27-244.17-266.76-283.25-269.48-355.93-285.31-130.78-13.25
EPS (Recurring)-0.53-0.80-1.15-1.57-1.42-1.67-1.01-0.53-0.05
EPS (Basic, Before Extraordinaries)-0.53-0.96-1.16-1.46-1.43-2.14-1.52-0.70-0.07
EPS (Diluted)-0.53-0.96-1.16-1.46-1.43-2.14-1.52-0.70-0.07
EBITDA-165.87-178.21-255.98-294.94-241.32-228.68-150.95-95.50-8.22
Non-Operating Income (Expense)7.466.155.969.893.090.980.842.83-0.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense22.6725.4637.6835.5338.3422.365.831.090.06
Shares Outstanding299.52266.73223.92197.86191.02184.93187.51187.34187.34
Market Capitalization728.11728.11363.93804.30753.372,923.132,974.12--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A3.002.202.393.053.202.863.655.69
Gross Profit-3.00-2.20-2.39-3.05-3.20-2.86-3.65-5.69
Selling, General and Administrative Excl. Other33.9646.8635.4849.5742.3141.2145.1248.06
Research and Development26.0236.0824.0237.3832.0230.8733.6330.78
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-36.96-49.06-37.87-52.62-45.51-44.06-48.77-53.75
Interest Expense0.000.00-0.000.000.00--
Unusual Expense-55.4716.3610.748.58-1.9950.911.86-2.89
Net Income Before Taxes20.40-63.63-47.21-58.83-42.15-93.80-49.39-49.07
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income20.40-63.63-47.21-58.83-42.15-93.80-49.39-49.07
Net Income From Continuing Operations20.40-63.63-47.21-58.83-42.15-93.80-49.39-49.07
Net Income20.40-63.63-47.21-58.83-42.15-93.80-49.39-49.07
EPS (Recurring)-0.06-0.18-0.14-0.19-0.17-0.24-0.20-0.22
EPS (Basic, Before Extraordinaries)0.07-0.22-0.17-0.21-0.16-0.39-0.21-0.21
EPS (Diluted)0.07-0.22-0.17-0.21-0.16-0.39-0.21-0.21
EBITDA-33.96-46.86-35.48-49.57-42.31-41.21-45.12-48.06
Non-Operating Income (Expense)1.901.781.402.371.361.181.241.80
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.335.345.666.345.486.637.026.44
Shares Outstanding299.52299.31269.82266.73262.26230.51225.46223.92
Market Capitalization728.11971.24768.581,084.11918.39615.77378.04363.93

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments142.58156.33209.03430.06551.00378.26138.9830.63
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets6.104.484.4914.377.116.205.281.97
Total Current Assets148.68160.81213.51444.44558.10384.47144.2632.60
Net Property, Plant & Equipment65.22135.27145.59159.40161.78109.9469.310.58
Total Investments and Advances0.000.000.0014.468.822.141.780.82
Intangible Assets199.82199.82199.82199.82199.82199.82199.820.00
Deferred Tax Assets9.83-------
Other Assets3.175.126.374.60200.8833.920.520.34
Total Assets426.72501.02565.30822.721,129.41730.30415.7034.33
Short Term Debt Incl. Current Port. of LT Debt14.9412.5313.2012.399.163.711.850.00
Accounts Payable1.675.214.112.862.222.250.000.29
Other Current Liabilities62.1227.6947.1896.2587.8625.4917.981.50
Total Current Liabilities78.7345.4364.49111.5099.2331.4519.831.78
Long Term Debt63.9281.6690.9095.86101.7868.2046.360.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities9.83-------
Other Liabilities113.36123.42122.41116.04199.89198.9474.690.01
Total Liabilities265.84250.52277.79323.40400.90298.58140.881.80
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00852.90417.3645.72
Common Equity160.88250.50287.51499.31728.50-421.18-142.54-13.19
Total Shareholders Equity160.88250.50287.51499.31728.50431.71274.8232.53
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity160.88250.50287.51499.31728.50431.71274.8232.53
Total Liabilities & Stockholders Equity426.72501.02565.30822.721,129.41730.30415.7034.33
Book Value Per Share0.601.121.452.613.94-2.25-0.76-0.07
Tangible Book Value Per Share-0.150.230.441.572.86-3.31-1.83-0.07
Full-Time Employees142194328421383265--
Price to Book Ratio4.041.242.201.333.933.47--
Return on Assets-52.64-50.03-40.81-27.61-38.28-49.79-58.12-
Return on Equity-118.70-99.17-72.00-43.90-61.36-80.76-85.10-
Return on Invested Capital-108.61-80.31-74.85-45.28-42.87-57.07-40.72-40.72
Quick Ratio1.893.543.313.995.6212.227.2818.26
Current Ratio1.893.543.313.995.6212.227.2818.26

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-149.27-244.17-266.76-283.25-269.48-355.93-285.31-130.78-13.25
Depreciation10.6512.7525.1737.8227.7317.9110.173.920.00
Other Funds (Non Cash)5.2997.7019.62-26.76-55.8577.16131.0038.370.06
Funds from Operations-133.33-133.71-221.97-272.19-297.59-260.86-144.14-96.03-13.19
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-8.23-10.11-1.1918.617.549.806.1610.53-0.31
Cash from Operating Activities-141.56-143.83-223.15-253.58-290.05-251.05-137.98-85.50-13.49
Capital Expenditures-3.57-0.94-33.43-20.03-20.88-29.86-23.87-26.18-0.46
Net Assets From Acquisitions0.000.000.000.000.000.000.00-3.190.00
Sale of Fixed Assets and Businesses0.981.430.000.000.000.000.000.060.00
Purchase or Sale of Investments-29.63-40.7350.88192.04231.44-211.36-228.69-58.540.00
Purchase of Investments-159.46-87.29-226.06-157.74-78.69-491.39-387.43-141.520.00
Sale Or Maturity of Investments129.8246.56276.95349.79310.13280.02158.7482.980.00
Other Uses0.000.000.000.000.00-4.570.000.00-0.32
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-32.23-40.2417.45172.01210.56-245.80-252.56-87.86-0.78
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock21.85129.08192.0031.654.91631.75435.69223.7445.72
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock21.85129.08192.0031.654.91631.75435.69223.7445.72
Proceedsfrom Stock Options20.37126.40181.0031.650.60626.40435.69223.7445.72
Issuance or Reduction of Debt, Net-0.37-0.357.740.000.000.000.000.000.00
Change in Long Term Debt-0.37-0.357.740.000.000.000.000.000.00
Issuance of Long Term Debt0.000.007.740.000.000.000.000.000.00
Reduction of Long Term Debt-0.37-0.350.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow89.620.000.000.000.000.000.00-0.010.00
Other Financing Activities Uses0.000.000.000.000.000.000.00-0.010.00
Cash from Financing Activities111.10128.73199.7531.654.91631.75435.69223.7345.72
Net Change in Cash-62.69-55.33-5.95-49.92-74.58134.9045.1450.3631.45
Free Cash Flow-145.13-144.77-256.58-273.61-310.93-280.92-161.85-111.69-13.96
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00-7.550.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments125.49164.69105.33142.58157.2576.87
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets6.825.946.366.104.515.63
Total Current Assets132.31170.63111.69148.68161.7682.50
Net Property, Plant & Equipment43.4460.5261.5265.2270.6476.10
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets199.82199.82199.82199.82199.82199.82
Deferred Tax Assets---9.83--
Other Assets0.550.550.563.173.223.22
Total Assets376.13431.52373.59426.72435.43361.64
Short Term Debt Incl. Current Port. of LT Debt13.3214.5114.8814.9414.3713.83
Accounts Payable1.951.362.121.671.862.27
Other Current Liabilities59.62107.8969.2662.1219.2917.34
Total Current Liabilities74.88123.7586.2778.7335.5133.44
Long Term Debt40.5259.2360.4563.9267.8771.66
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---9.83--
Other Liabilities80.3693.97107.64113.36136.74133.99
Total Liabilities195.76276.95254.35265.84240.12239.09
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity180.36154.57119.24160.88195.31122.56
Total Shareholders Equity180.36154.57119.24160.88195.31122.56
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity180.36154.57119.24160.88195.31122.56
Total Liabilities & Stockholders Equity376.13431.52373.59426.72435.43361.64
Book Value Per Share0.600.520.440.600.740.53
Tangible Book Value Per Share-0.06-0.15-0.30-0.15-0.02-0.34
Full-Time Employees---142--
Price to Book Ratio4.047.904.775.476.682.94
Return on Assets-36.79-53.41-59.09-52.64-47.13-51.45
Return on Equity-79.47-152.87-147.41-118.70-96.11-109.12
Return on Invested Capital9.24-29.76-26.27-26.17-16.02-48.30
Quick Ratio1.771.381.291.894.552.47
Current Ratio1.771.381.291.894.552.47

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income20.40-63.63-47.21-58.83-42.15-93.80
Depreciation2.972.232.393.053.192.86
Other Funds (Non Cash)-55.8727.4913.9519.728.8461.21
Funds from Operations-32.49-33.91-30.87-36.05-30.13-29.73
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-6.261.12-6.513.410.70-3.37
Cash from Operating Activities-38.75-32.79-37.38-32.64-29.43-33.10
Capital Expenditures-0.79-1.62-0.29-0.87-0.040.11
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.040.020.250.660.140.38
Purchase or Sale of Investments23.09-85.9249.48-16.28-48.127.19
Purchase of Investments-16.11-101.67-5.59-36.08-49.530.00
Sale Or Maturity of Investments39.2115.7555.0619.801.417.19
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities22.35-87.5249.44-16.50-48.027.68
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.123.930.0617.74109.630.59
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.123.930.0617.74109.630.59
Proceedsfrom Stock Options0.003.690.0016.68109.470.25
Issuance or Reduction of Debt, Net-0.09-0.09-0.09-0.09-0.09-0.09
Change in Long Term Debt-0.09-0.09-0.09-0.09-0.09-0.09
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.09-0.09-0.09-0.09-0.09-0.09
Net Financing Active Other Cash Flow-0.0289.74-0.100.000.000.06
Other Financing Activities Uses0.000.10-0.100.000.000.06
Cash from Financing Activities0.0093.58-0.1317.65109.540.56
Net Change in Cash-16.40-26.7311.93-31.4932.09-24.86
Free Cash Flow-39.54-34.41-37.67-33.51-29.47-32.99

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3021.72%40.6M187.0M3.18M
2026-10-1521.87%40.8M186.8M3.19M
2026-09-3020.73%38.7M186.8M3.07M
2026-09-1522.15%41.4M186.8M3.03M
2026-08-3122.25%41.6M186.8M3.09M
2026-08-1422.78%42.6M186.9M3.29M
2026-07-3124.26%42.1M173.7M3.64M
2026-07-1522.87%39.7M173.7M3.76M
2026-06-3022.27%38.7M173.8M3.91M
2026-06-1523.42%40.7M173.7M3.73M
2026-05-2921.72%39.3M181.1M3.63M
2026-05-1515.39%38.5M250.0M3.33M
2026-04-3024.76%41.1M166.0M2.93M
2026-04-1524.60%40.9M166.2M2.82M
2026-03-3123.70%39.4M166.2M2.57M
2026-03-1322.58%37.5M166.2M2.75M
2026-02-2721.56%35.8M166.2M3.25M
2026-02-1322.48%37.3M165.8M3.64M
2026-01-3022.24%36.9M165.9M3.93M
2026-01-1522.38%37.1M165.9M4.56M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.501.352.350.0030.3060.000.000.975-0.0210.000
call1.000.901.901.4413.5670.000.000.905-0.0330.001
call1.500.351.300.887.5121.000.000.824-0.0320.001
call2.000.051.000.606.4165.000.000.708-0.0260.001
call2.500.000.200.101.7356270.000.473-0.0140.001
call5.000.000.050.053.2832,7770.000.107-0.0120.001
call7.500.000.450.014.9863.000.000.142-0.0230.001
put0.500.000.750.0018.2840.000.00-0.024-0.0210.000
put1.000.000.750.009.5070.000.00-0.095-0.0330.001
put1.500.000.750.006.0380.000.00-0.175-0.0310.001
put2.000.000.550.002.1050.000.00-0.268-0.0140.001
put2.500.050.350.331.6361,0190.00-0.547-0.0150.001
put5.002.203.200.007.2010.000.00-0.893-0.0120.001
put7.504.705.700.008.6540.000.00-0.856-0.0230.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-05SCHEDULE 13G/ASEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-058-KCurrent report2026-06-04SEC
2026-05-21SCHEDULE 13GSEC
2026-05-158-KCurrent report2026-05-15SEC
2026-05-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-04-24ARSAnnual report to security holders. 2025-12-31SEC
2026-04-24DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-04SEC
2026-04-248-KCurrent report2026-04-22SEC
2026-04-13424B5SEC
2026-04-138-KCurrent report2026-04-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC12.46%
Flagship Pioneering, LLC8.98%
RA CAPITAL MANAGEMENT, L.P.6.74%
BlackRock, Inc.5.99%
STATE STREET CORP4.03%
CANADA PENSION PLAN INVESTMENT BOARD3.67%
VANGUARD CAPITAL MANAGEMENT LLC3.01%
BANK OF AMERICA CORP /DE/2.07%
GEODE CAPITAL MANAGEMENT, LLC1.55%
Marex Group Ltd1.43%

Funds

Fund% owned
Fidelity Growth Company Fund3.51%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.54%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.25%
iShares Russell 2000 ETF1.73%
Fidelity Growth Company K6 Fund1.04%
Fidelity Series Growth Company Fund0.95%
Fidelity Small Cap Index Fund0.72%
VANGUARD EXTENDED MARKET INDEX FUND0.69%
iShares Russell 2000 Growth ETF0.60%
iShares Biotechnology ETF0.46%

OakChart. SANA. Cached 15 minutes.